BioForm Medical to Announce Financial Results For Quarter Ended March 31, 2008, Third Quarter of Fiscal 2008, and Host Conferenc

SAN MATEO, Calif., April 10 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. (Nasdaq: BFRM) announced that on Thursday, May 1, 2008, it will report its financial results for the quarter ended March 31, 2008, which is its third quarter fiscal year 2008. The Company will issue the earnings press release after the NASDAQ Global Market closes and will hold a conference call with investors at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

BioForm Medical Chief Executive Officer Steve Basta and Chief Financial Officer Derek Bertocci will discuss the Company's results for the quarter ended March 31, 2008. The conference call will be webcast live on the Investor Relations section of BioForm Medical's website at www.bioform.com. The online archive of the broadcast will be available approximately 90 minutes after the live call and will continue to be available for four weeks.

The conference call may be accessed by dialing 877-591-4956 for callers in the U.S. and 719-325-4880 for international callers. Please notify the operator that you would like to join "BioForm Medical's Third Quarter Earnings Call" and provide the participant code "7284989", if prompted.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm is dedicated to bringing doctors and their patients safe and effective products for use in the dermatology, plastic surgery and ENT markets. BioForm's products include Radiesse(R), a long-lasting filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite(R) for treating female stress urinary incontinence which is marketed through a partnership with Boston Scientific Corporation. BioForm has licensed U.S. marketing rights to Aethoxysklerol(R), the worldwide leading sclerotherapy agent, which is currently being evaluated in a Phase III clinical trial. BioForm has also licensed BioGlue, a new surgical adhesive product for plastic surgery applications, which is being developed in a partnership with CryoLife, Inc.

SOURCE BioForm Medical, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.